In a groundbreaking development, BioMerieux has expanded its initial 16% stake in Lumed, solidifying its grip on the Canadian clinical software innovator. The acquisition, valued at €9 million, positions BioMerieux as the sole proprietor of Lumed’s share capital.
BioMerieux acquires Lumed: A Pillar in Antimicrobial Resistance
Known for its pioneering software, Lumed has been a crucial ally for BioMerieux since their collaboration commenced in October 2017. Lumed’s expertise lies in empowering clinicians to adhere to antimicrobial prescription guidelines, a key strategy in the battle against drug resistance.
Legal Counsel and the Path to Acquisition
Therrien Couture Joli-Coeur, a prominent Canadian law firm, played a pivotal role in advising Lumed on the acquisition. Details regarding BioMerieux’s legal counsel remain undisclosed.
BioMerieux acquires Lumed : The Fight Against Drug Resistance
The collaboration between BioMerieux and Lumed centers around enhancing clinical practices for infectious diseases, with a specific focus on governing antimicrobials—comprising antibiotics, antivirals, antifungals, and antiparasitics. The grave consequence of resistance occurs when microorganisms no longer respond to these medications.
BioMerieux acquires Lumed : Lumed’s Impactful Software
Lumed’s software equips healthcare professionals with vital data to implement programs combating antimicrobial resistance and enhancing infection control. The innovative technology contributes significantly to optimizing care delivery processes, reducing costs, and effectively managing patients.
BioMerieux’s Vision for the Future
“For BioMerieux, it is essential that we extend the scope of diagnostic testing beyond the laboratory itself,” emphasized Jennifer Zinn, Executive Vice President of Clinical Operations at BioMerieux. “With Lumed, we provide solutions for antimicrobial stewardship teams to improve their daily workflow.”
Synergy in Innovation
Vincent Nault, Chief Executive of Lumed, expressed enthusiasm about the merger, stating, “Joining forces with BioMerieux aligns with our commitment to advancing antimicrobial stewardship and infection prevention. Combining Lumed’s innovative software solutions with BioMérieux’s global reach and expertise in diagnostics will create a powerful synergy.”
Market Response and Strategic Growth
Shares in BioMérieux, listed on the Euronext Paris exchange, witnessed a 1.14% surge on Monday morning, reaching €99.06, compared to Friday’s closing value of €97.94. BioMérieux views this acquisition as a crucial step in expanding its portfolio of data analytics products.
BioMerieux acquires Lumed : Closing Thoughts
In the ever-evolving landscape of biotechnology, BioMerieux’s acquisition of Lumed emerges as a formidable move, propelling the fight against antimicrobial resistance into a new era. The €9 million deal not only signifies a financial investment but a commitment to innovation and global health.
